🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to determine if the novel oral agent VT-1161 i...
Status
Completed
Location
Univ Alabama at Birmingham
Start Date
2013-08
Trial ID
NCT01891305
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast in...
Status
Completed
Location
34
Start Date
2019-03-13
Trial ID
NCT03840616
Treatments Being Tested
Several properties of VT-1161 suggest that it might be a safer and more eff...
Status
Completed
Location
The Kirklin Clinic of UAB Hospital
Start Date
2015-02-17
Trial ID
NCT02267356
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast in...
Status
Completed
Location
31215
Start Date
2018-08-23
Trial ID
NCT03561701
Treatments Being Tested
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51)...
Status
Completed
Location
University of Alabama Birmingham
Start Date
2015-02-10
Trial ID
NCT02267382
The purpose of this study is to determine if the novel oral agent VT-1161 i...
Status
Completed
Location
Altus Research
Start Date
2013-08
Trial ID
NCT01891331
Treatments Being Tested
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast in...
Status
Completed
Location
31123
Start Date
2018-08-16
Trial ID
NCT03562156
Treatments Being Tested
Oteseconazole is a novel, oral, highly selective inhibitor of fungal CYP51....
Status
Not Yet Recruiting
Location
Multiple Locations
Start Date
2025-08-10
Trial ID
NCT07044947
Treatments Being Tested